Institute for Quality and Efficiency in Health Care

The Institute for Quality and Efficiency in Healthcare (IQWiG) (German: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen) is a German agency responsible for assessing the quality and efficiency of medical treatments, including drugs, non-drug interventions (e.g. surgical procedures), diagnostic and screening methods, and treatment and disease management. IQWiG also supplies health information to patients and the general public.

Institute for Quality and Efficiency in Health Care
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Agency overview
Formed2004 (2004)
JurisdictionGermany
Agency executives
  • Dr Jürgen Windeler
  • Dr Stefan Lange
Parent departmentFederal Ministry of Health
WebsiteIQWiG website

The organization is independent of the pharmaceutical industry, contracted solely by the Federal Ministry of Health and the Joint Federal Committee.

Structure

IQWiG was founded in 2004 under the directorship of Dr Peter Sawicki, who was replaced in September 2010 by Dr Jürgen Windeler. Its deputy director is Dr Stefan Lange.

IQWiG is divided into the following departments, which publish reports:

  • Drug Assessment
  • Non-Drug Interventions
  • Quality of Health Care
  • Medical Biometry
  • Health Economics

General health information, written in plain language, is additionally produced by a Health Information department.

These departments are also supported by Administration and Communication departments.

It regularly communicates with similar organisations in other countries, such as with the National Institute for Health and Clinical Excellence (NICE) in the UK and the Haute Autorité de Santé (HAS) in France.

Most noticed reports

IQWiG hit international headlines in October 2010 with a report slamming Reboxetine as inefficient and harmful.[1]

Similarly, in September 2010, another study rebuffed the use of Venlafaxine and Duloxetine as first-line treatment in major depression, but recommend them as a second line option.[2]

The use of Memantine in Alzheimer's patients was deemed as insufficiently supported by scientific evidence.[3] This led Merz Pharma to provide additional data, and the Institute to change its evaluation.[4]

A report in 2010 indicated that long-acting insulin analogues showed no benefits over intermediate-acting insulin for the treatment of type I diabetes.[5]

See also

References
  1. "Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials". British Medical Journal. 341: c4737. 2010. doi:10.1136/bmj.c4737. PMC 2954275. PMID 20940209.
  2. Schueler YB; Koesters M; Wieseler B; Grouven U; Kromp M; Kerekes MF; Kreis J; Kaiser T; et al. (2010). "A systematic review of duloxetine and venlafaxine in major depression, including unpublished data". Acta Psychiatrica Scandinavica. 123 (4): 247–265. doi:10.1111/j.1600-0447.2010.01599.x. PMID 20831742. S2CID 2262158.
  3. Memantine in Alzheimer’s disease: Results of the unpublished studies IE2101 and MEM-MD-22 as well as unpublished responder analyses IQWiG Public release date: 2-Aug-2010
  4. [German cost agency changes tack on Alzheimer's drug https://web.archive.org/web/20111105185017/https://www.reuters.com/article/2011/04/26/germany-memantine-idUSLDE73P1LX20110426]
  5. Long-acting insulin analogues in the treatment of diabetes mellitus type 1 IQWiG Public release date: 19-Apr-2010
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.